(6-bromopyridin-3-yl)methyl methanesulfonate | 843646-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (6-bromopyridin-3-yl)methyl methanesulfonate
• CAS: 843646-70-8
• 化学式: C₇H₈BrNO₃S
• 分子量: 266.115
• InChiKey: LPKNDAZRNGHMIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (6-bromopyridin-3-yl)methyl methanesulfonate 在 lithium bromide 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 2-溴-5-(溴甲基)吡啶
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  摘要：

  New heterocyclic analogues of the potent biphenyl class derived from antitubercular drug PA-824 were prepared, aiming to improve aqueous solubility but maintain high metabolic stability and efficacy. The strategy involved replacement of one or both phenyl groups by pyridine, pyridazine, pyrazine, or pyrimidine, in order to reduce lipophilicity. For para-linked biaryls, hydrophilicities (ClogP) correlated with measured solubilities, but highly soluble bipyridine analogues displayed weak antitubercular activities. A terminal pyridine or proximal heterocycle allowed retention of potency and provided solubility improvements, particularly at low pH, with examples from the latter classes displaying the better in vivo efficacies, high metabolic stabilities, and excellent pharmacokinetics. Five such compounds were >100-fold better than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection, and two orally bioavailable pyridine analogues (3-4-fold more soluble than the parent at low pH) were superior to antitubercular drug OPC-67683 in a chronic infection model.

  DOI：

  10.1021/jm101288t
• 作为产物：
  描述：

  2-溴-5-醛基吡啶 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.5h， 生成 (6-bromopyridin-3-yl)methyl methanesulfonate
  参考文献：
  名称：

  [EN] INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
  [FR] INHIBITEURS DE PROTÉINE TYROSINE KINASE

  摘要：

  本发明提供了用于治疗对激酶活性抑制产生响应的疾病的新化合物和方法，例如对蛋白酪氨酸激酶活性抑制产生响应的疾病，例如对生长因子受体的蛋白酪氨酸激酶活性抑制产生响应的疾病，例如对受体型酪氨酸激酶信号传导抑制产生响应的疾病，或例如对VEGF受体信号传导抑制产生响应的疾病。

  公开号：

  WO2013044360A1

文献信息

• [EN] PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE TYPE PYRAZOLO[4,3-C]CINNOLIN-3-ONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010096338A1

  公开（公告）日：2010-08-26

  The present invention is directed to pyrazolo [4,3-c] cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]咖啉-3-酮化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• 羟基嘌呤类化合物及其应用
  申请人：广东众生睿创生物科技有限公司

  公开号：CN105566324B

  公开（公告）日：2020-04-03

  本发明公开了一系列羟基嘌呤类化合物及其作为PDE2或TNFa抑制剂的应用，具体公开了式(Ⅰ)所示化合物、其互变异构体或其药学上可接受的盐。
• 硝基咪唑类化合物及其制备方法和用途
  申请人：南京长澳医药科技有限公司

  公开号：CN112300192B

  公开（公告）日：2023-08-11

  本发明公开了一种新型硝基咪唑类化合物及其制备方法和用途。所述硝基咪唑类化合物具有下述通式(I)：
• [EN] HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS D'UN RÉCEPTEUR M1 DE CINNOLINE FUSIONNÉE HÉTÉROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010123716A1

  公开（公告）日：2010-10-28

  The present invention is directed to heterocyclic fused cinnoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的杂环融合喹啉化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗M1受体介导的疾病中使用这些化合物和组合物。
• [EN] HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS<br/>[FR] HÉTÉROARYL-CARBOXAMIDES COMME INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：ORYZON GENOMICS SA

  公开号：WO2018219478A1

  公开（公告）日：2018-12-06

  The invention relates to heteroaryl-carboxamides as described herein, useful as histone demethyiase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

  本发明涉及如本文所述的杂环基-羧酰胺，其作为组蛋白去甲基酶抑制剂具有用处。本发明还涉及包含这些化合物的药物组合物，以及它们在治疗中的应用，包括例如在癌症治疗中的应用。